Shares of Alexion fell more than 11 percent Friday as the office instituted an inter partes review for the drug, Soliris, in the blood disorder paroxysmal nocturnal hemoglobinuria.
The decision in favor of Broad Institute of MIT and Harvard by a panel of judges at the US Court of Appeals for the Federal Circuit leaves UC Berkeley with few options to appeal further.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.